In particular, serious pericardial effusion (ie, requiring percutaneous or surgical drainage) occurred in 4.8% of patients in the percutaneous LAA closure arm. Another occlusion device, PLAATO [percutaneous LAA transcatheter occlusion], has not been tested in a randomized trial but has been evaluated in prospective, multicenter cohort studies in patients ineligible for warfarin.101,102 At this time, we make Table 11 [Section 2.1.12] Bleeding Risk Scores Low Moderate High Calculation of Bleeding Risk Score Outpatient Bleeding Risk Age 65 y GI bleed in past 2 wk Previous stroke Comorbidities (recent MI, Hct,30%, diabetes, or creatinine.1.5 mg/dL) Hepatic or renal disease Ethanol abuse Malignancy Older age (.75 yr) Reduced platelet count or function Hypertension (uncontrolled) Anemia Genetic factors (CYP2C9 polymorphisms) Excessive fall risk Stroke 2 points for: Rebleeding risk (ie, prior bleed) (0.273diabetes)1(0.863anemia)1(0.323antiplatelet drug use), with 1 point for presence of each and 0 if absent Abnormal renal/liver function (1 point each) Stroke Bleeding history or predisposition Labile INR Elderly (eg, age.65 y) Drugs (eg, concomitant antiplatelet/NSAID) or alcohol (1 point each) Maximum 9 points Hct5hematocrit; NSAID5nonsteroidal antiin ammatory drug. See Table 1 and 8 legends for expansion of other abbreviations. 